JP2009504622A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009504622A5 JP2009504622A5 JP2008525620A JP2008525620A JP2009504622A5 JP 2009504622 A5 JP2009504622 A5 JP 2009504622A5 JP 2008525620 A JP2008525620 A JP 2008525620A JP 2008525620 A JP2008525620 A JP 2008525620A JP 2009504622 A5 JP2009504622 A5 JP 2009504622A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- psychosis
- dihydrotetrabenazine
- schizophrenia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 208000028017 Psychotic disease Diseases 0.000 claims 14
- 201000000980 schizophrenia Diseases 0.000 claims 7
- 230000002265 prevention Effects 0.000 claims 5
- 206010012239 Delusion Diseases 0.000 claims 4
- 231100000868 delusion Toxicity 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 208000024891 symptom Diseases 0.000 claims 4
- 238000011282 treatment Methods 0.000 claims 4
- 208000004547 Hallucinations Diseases 0.000 claims 3
- 208000020925 Bipolar disease Diseases 0.000 claims 2
- 201000006347 Intellectual Disability Diseases 0.000 claims 2
- 210000004556 brain Anatomy 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 206010021402 Illogical thinking Diseases 0.000 claims 1
- 206010024229 Leprosy Diseases 0.000 claims 1
- 206010033864 Paranoia Diseases 0.000 claims 1
- 208000027099 Paranoid disease Diseases 0.000 claims 1
- 206010034038 Parotitis Diseases 0.000 claims 1
- 206010034719 Personality change Diseases 0.000 claims 1
- 206010053632 Reactive psychosis Diseases 0.000 claims 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 230000003542 behavioural effect Effects 0.000 claims 1
- 208000028683 bipolar I disease Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- 201000002545 drug psychosis Diseases 0.000 claims 1
- 239000003792 electrolyte Substances 0.000 claims 1
- 230000008451 emotion Effects 0.000 claims 1
- 230000002996 emotional effect Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 201000004792 malaria Diseases 0.000 claims 1
- 230000003340 mental effect Effects 0.000 claims 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical group CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 208000019206 urinary tract infection Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0516167.4A GB0516167D0 (en) | 2005-08-06 | 2005-08-06 | Pharmaceutical compounds |
| GB0516790A GB0516790D0 (en) | 2005-08-16 | 2005-08-16 | Pharmaceutical compounds |
| PCT/GB2006/002936 WO2007017654A1 (en) | 2005-08-06 | 2006-08-04 | 3, hb cis dihydrotetrabanezine for the treatment of schizophrenia and other psychoses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009504622A JP2009504622A (ja) | 2009-02-05 |
| JP2009504622A5 true JP2009504622A5 (enExample) | 2009-09-24 |
Family
ID=37400949
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008525620A Ceased JP2009504622A (ja) | 2005-08-06 | 2006-08-04 | 医薬化合物 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20110257220A1 (enExample) |
| EP (2) | EP1855677B1 (enExample) |
| JP (1) | JP2009504622A (enExample) |
| KR (1) | KR20080033500A (enExample) |
| AT (2) | ATE415968T1 (enExample) |
| AU (1) | AU2006277753B2 (enExample) |
| CA (1) | CA2620960A1 (enExample) |
| CY (1) | CY1108843T1 (enExample) |
| DE (1) | DE602006004009D1 (enExample) |
| DK (1) | DK1855677T3 (enExample) |
| ES (1) | ES2318771T3 (enExample) |
| HR (1) | HRP20090074T3 (enExample) |
| MX (1) | MX2008001549A (enExample) |
| NZ (1) | NZ566011A (enExample) |
| PL (1) | PL1855677T3 (enExample) |
| PT (1) | PT1855677E (enExample) |
| RS (1) | RS50807B (enExample) |
| RU (1) | RU2407743C2 (enExample) |
| SI (1) | SI1855677T1 (enExample) |
| WO (1) | WO2007017654A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2081929T3 (da) | 2006-11-08 | 2013-04-15 | Neurocrine Biosciences Inc | Substituerede 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11B-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol-forbindelser og fremgangsmåder angående disse |
| US8008500B2 (en) | 2007-06-08 | 2011-08-30 | General Electric Company | Intermediates useful for making tetrabenazine compounds |
| US8053578B2 (en) | 2007-11-29 | 2011-11-08 | General Electric Company | Alpha-fluoroalkyl dihydrotetrabenazine imaging agents and probes |
| GB0810857D0 (en) * | 2008-06-13 | 2008-07-23 | Cambridge Lab Ireland Ltd | Pharmaceutical compounds |
| GB2463283A (en) * | 2008-09-08 | 2010-03-10 | Cambridge Lab | 3,11b-cis-dihydrotetrabenazine for use in treating asthma |
| GB2463451A (en) | 2008-09-08 | 2010-03-17 | Cambridge Lab | 3, 11b cis-dihydrotetrabenazine compounds for use in the treatment of dementia |
| CA2801061A1 (en) | 2010-06-01 | 2011-12-08 | Auspex Pharmaceuticals, Inc. | Benzoquinolone inhibitors of vmat2 |
| JP6010108B2 (ja) | 2011-04-01 | 2016-10-19 | スリーエム イノベイティブ プロパティズ カンパニー | トリアジン系紫外線吸収剤を含むフィルム |
| CA2936823A1 (en) | 2014-01-27 | 2015-07-30 | Auspex Pharmaceuticals, Inc. | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| CA2938581C (en) | 2014-02-07 | 2023-02-28 | Neurocrine Biosciences, Inc. | Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof |
| IL284874B2 (en) | 2015-10-30 | 2023-10-01 | Neurocrine Biosciences Inc | Valbenazine salts and polymorphs thereof |
| LT3394057T (lt) | 2015-12-23 | 2022-06-27 | Neurocrine Biosciences, Inc. | Sintezės būdas, skirtas pagaminti (s)-(2r,3r,11br)-3-izobutil-9,10-dimetoksi-2,3,4,6,7,11b-heksahidro-1h-pirido[2,1-a]izochinolin-2-ilo 2-amino-3-metilbutanoato di(4-metilbenzensulfonatą) |
| TW202345829A (zh) * | 2016-12-02 | 2023-12-01 | 美商紐羅克里生物科學有限公司 | 戊苯那嗪（valbenazine）於治療精神分裂症或情感性精神分裂症之用途 |
| KR20230169457A (ko) | 2017-01-27 | 2023-12-15 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 특정 vmat2 억제제의 투여 방법 |
| GB201705304D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| GB201705302D0 (en) * | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| GB201705303D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| GB201705306D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| GB201705305D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| RS66714B1 (sr) | 2017-09-21 | 2025-05-30 | Neurocrine Biosciences Inc | Formulacija visoke doze valbenazina i sastavi, postupci i kompleti povezani sa njim |
| MX2020003421A (es) | 2017-10-10 | 2020-07-20 | Neurocrine Biosciences Inc | Metodos para la administracion de ciertos inhibidores del transportador vesicular de monoamina 2 (vmat2). |
| KR20250070134A (ko) | 2017-10-10 | 2025-05-20 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 특정 vmat2 억제제의 투여 방법 |
| GB201808464D0 (en) | 2018-05-23 | 2018-07-11 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compounds for use in treating huntington's disease |
| MA53239A (fr) | 2018-08-15 | 2022-05-04 | Neurocrine Biosciences Inc | Procédés d'administration de certains inhibiteurs de vmat2 |
| US10940141B1 (en) | 2019-08-23 | 2021-03-09 | Neurocrine Biosciences, Inc. | Methods for the administration of certain VMAT2 inhibitors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2830993A (en) * | 1958-04-15 | Quinolizine derivatives | ||
| US2843591A (en) | 1958-07-15 | Method for preparing same | ||
| CA2058640A1 (en) * | 1991-01-25 | 1992-07-26 | Richard R. Scherschlicht | Tricyclic pyridone derivative |
| US6087376A (en) * | 1997-02-05 | 2000-07-11 | University Of Kentucky Research Foundation | Use of lobeline compounds in the treatment of central nervous system diseases and pathologies |
| FR2770215B1 (fr) * | 1997-10-28 | 2000-01-14 | Pf Medicament | Derives d'aminomethyl-benzo[a]quinolizidine, leur preparation et leur application en therapeutique pour les maladies neurodegeneratives |
| GB2410947B (en) * | 2004-02-11 | 2008-09-17 | Cambridge Lab Ltd | Pharmaceutical compounds |
-
2006
- 2006-08-04 AT AT06765238T patent/ATE415968T1/de active
- 2006-08-04 CA CA002620960A patent/CA2620960A1/en not_active Abandoned
- 2006-08-04 PT PT06765238T patent/PT1855677E/pt unknown
- 2006-08-04 JP JP2008525620A patent/JP2009504622A/ja not_active Ceased
- 2006-08-04 KR KR1020087005308A patent/KR20080033500A/ko not_active Withdrawn
- 2006-08-04 MX MX2008001549A patent/MX2008001549A/es active IP Right Grant
- 2006-08-04 RU RU2008108623/04A patent/RU2407743C2/ru not_active IP Right Cessation
- 2006-08-04 PL PL06765238T patent/PL1855677T3/pl unknown
- 2006-08-04 EP EP06765238A patent/EP1855677B1/en active Active
- 2006-08-04 DE DE602006004009T patent/DE602006004009D1/de active Active
- 2006-08-04 US US11/997,591 patent/US20110257220A1/en not_active Abandoned
- 2006-08-04 HR HR20090074T patent/HRP20090074T3/xx unknown
- 2006-08-04 SI SI200630210T patent/SI1855677T1/sl unknown
- 2006-08-04 ES ES06765238T patent/ES2318771T3/es active Active
- 2006-08-04 DK DK06765238T patent/DK1855677T3/da active
- 2006-08-04 AU AU2006277753A patent/AU2006277753B2/en not_active Expired - Fee Related
- 2006-08-04 WO PCT/GB2006/002936 patent/WO2007017654A1/en not_active Ceased
- 2006-08-04 RS RSP-2009/0055A patent/RS50807B/sr unknown
- 2006-08-04 NZ NZ566011A patent/NZ566011A/en not_active IP Right Cessation
- 2006-08-04 AT AT08170385T patent/ATE534391T1/de active
- 2006-08-04 EP EP08170385A patent/EP2050451B1/en active Active
-
2009
- 2009-02-26 CY CY20091100221T patent/CY1108843T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012520249A5 (enExample) | ||
| JP2009533356A5 (enExample) | ||
| JP2019532079A5 (enExample) | ||
| TN2012000231A1 (en) | Quinoline amide m1 receptor positive allosteric modulators | |
| JP2005506370A5 (enExample) | ||
| BR112015008962A2 (pt) | silicato de zircônio microporoso para o tratamento de hipercalemia | |
| RU2008108623A (ru) | Фармацевтические соединения | |
| MX2012012952A (es) | Compuestos de 2, 5, 6, 7,-tetrahidro-[1, 4] oxazepin-3-ilamina o 2, 3, 6, 7-tetrahidro-[1, 4] oxazepin-5-ilamina. | |
| WO2010080452A3 (en) | siRNA COMPOUNDS AND METHODS OF USE THEREOF | |
| MX2009004362A (es) | Compuestos mediante benzoilo amino heterociclilo util en el tratamiento de una enfermedad a traves de glk. | |
| JP2009510044A5 (enExample) | ||
| BRPI0812729A2 (pt) | materiais e métodos para tratamento e diagnósticos de distúrbios associados com estresse oxidativo | |
| PH12018502445A1 (en) | Compositions and methods for treating negative symptoms in non-schizophrenic patients | |
| JP2017509686A5 (enExample) | ||
| JP2012521966A5 (enExample) | ||
| JP2014508758A5 (enExample) | ||
| JP2009501202A5 (enExample) | ||
| JP2007516193A5 (enExample) | ||
| ATE357453T1 (de) | Comt-inhibitoren | |
| MY142036A (en) | New quaternized quinuclidine esters | |
| WO2016033432A9 (en) | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition | |
| JP2011527317A5 (enExample) | ||
| Tészás et al. | Expanding the clinical spectrum of MYCN-related Feingold syndrome. | |
| NZ597657A (en) | Use sulphur particles less than 300 microns and sodium lignin sulfonate for treating diseases casused by microbial pathogenic infections | |
| WO2008034202A3 (en) | Use of ivermectin and derivates thereof for the treatment of amyotrophic lateral sclerosis |